Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone + anlotinib as second-line therapy for advanced soft tissue sarcoma (NOS)
ChiCTR2600124228Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2026
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and anlotinib in soft tissue sarcoma (STS), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-Free Survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
utideloneanlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2600124228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124228.